1-8 of 8
Authors: Michael D Ezekowitz
Save search
Sort by
Journal Article

Predictors of sinus rhythm 6 weeks after cardioversion of atrial fibrillation: a pre-planned post hoc analysis of the X-VeRT trial

PDF
Riccardo Cappato and others
EP Europace, Volume 23, Issue 10, October 2021, Pages 1539–1547, https://doi.org/10.1093/europace/euab084
Published: 13 June 2021
Journal Article

Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis

PDF
Mariëlle Kloosterman and others
EP Europace, Volume 22, Issue 6, June 2020, Pages 870–877, https://doi.org/10.1093/europace/euz360
Published: 26 March 2020
Journal Article

Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis

PDF
Jose L Merino and others
EP Europace, Volume 21, Issue 11, November 2019, Pages 1633–1638, https://doi.org/10.1093/europace/euz213
Published: 22 August 2019
Journal Article

Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study

PDF
Andreas Goette and others
EP Europace, Volume 20, Issue 12, December 2018, Pages 1936–1943, https://doi.org/10.1093/europace/euy141
Published: 27 June 2018
Journal Article

Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation— the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) study

PDF
Paolo Verdecchia and others
EP Europace, Volume 20, Issue 2, February 2018, Pages 253–262, https://doi.org/10.1093/europace/eux022
Published: 17 May 2017
Journal Article

Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation

PDF
Michael D. Ezekowitz and others
EP Europace, Volume 18, Issue 7, July 2016, Pages 973–978, https://doi.org/10.1093/europace/euv312
Published: 03 March 2016
Journal Article

Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial

PDF
Stefan H. Hohnloser and others
EP Europace, Volume 18, Issue 2, February 2016, Pages 184–190, https://doi.org/10.1093/europace/euv294
Published: 20 October 2015
Journal Article

2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society

PDF
Hugh Calkins and others
EP Europace, Volume 14, Issue 4, April 2012, Pages 528–606, https://doi.org/10.1093/europace/eus027
Published: 01 March 2012